ReviewInternational journal of nanomedicine2026
Liposomal Delivery Systems for Improved Delivery of Docetaxel Against Prostate Cancer.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generally, liposomes as a delivery system have been vastly designed for the delivery of therapeutic agents, to overcome various drawbacks, including resistance imposed to various conventional forms of these agents. They are significantly advantageous compared to other kinds of delivery systems because of their ability to deliver hydrophobic and hydrophilic therapeutic agents singly as monotherapy or combined as combinational therapy, owing to bilayer formation. Clinically, liposomes have been applied for delivery of therapeutic agents, with the aim of improving target-site-specificity and reducing toxicity to normal cells or tissues caused by chemotherapeutic drugs, which makes them relatively better options compared to the conventional forms of delivery system. Herein, a critical review which extensively discusses the various liposomal systems of delivery used for docetaxel (DTX) delivery against prostate cancer in the past decade, either alone as mono-therapeutical delivery or in combination with other therapeutic agents is presented. This review affirms to the potentials of employing liposomal systems of delivery for the effective targeted delivery of DTX against prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.